Search

Your search keyword '"Anand, Sarah"' showing total 26 results
Start Over Author "Anand, Sarah" Publication Year Range Last 3 years
26 results on '"Anand, Sarah"'

3. Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions

Author

Bracken, Sonali J., Suthers, Amy N., DiCioccio, Rachel A., Su, Hsuan, Anand, Sarah, Poe, Jonathan C., Jia, Wei, Visentin, Jonathan, Basher, Fahmin, Jordan, Collin Z., McManigle, William C., Li, Zhiguo, Hakim, Frances T., Pavletic, Steven Z., Bhuiya, Nazmim S., Ho, Vincent T., Horwitz, Mitchell E., Chao, Nelson J., and Sarantopoulos, Stefanie

Published
2024
Full Text
View/download PDF

4. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Author

Magenau, John, Jaglowski, Samantha, Uberti, Joseph, Farag, Sherif S., Riwes, Mary Mansour, Pawarode, Attaphol, Anand, Sarah, Ghosh, Monalisa, Maciejewski, John, Braun, Thomas, Devenport, Martin, Lu, Susan, Banerjee, Bhramori, DaSilva, Carolyn, Devine, Steven, Zhang, Mei-Jie, Burns, Linda J., Liu, Yang, Zheng, Pan, and Reddy, Pavan

Published
2024
Full Text
View/download PDF

5. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors

Author

Vasbinder, Alexi, Hoeger, Christopher W., Catalan, Tonimarie, Anderson, Elizabeth, Chu, Catherine, Kotzin, Megan, Xie, Jeffrey, Kaakati, Rayan, Berlin, Hanna P., Shadid, Husam, Perry, Daniel, Pan, Michael, Takiar, Radhika, Padalia, Kishan, Mills, Jamie, Meloche, Chelsea, Bardwell, Alina, Rochlen, Matthew, Blakely, Pennelope, Leja, Monika, Banerjee, Mousumi, Riwes, Mary, Magenau, John, Anand, Sarah, Ghosh, Monalisa, Pawarode, Attaphol, Yanik, Gregory, Nathan, Sunita, Maciejewski, John, Okwuosa, Tochukwu, and Hayek, Salim S.

Published
2023
Full Text
View/download PDF

7. Incidence of Restrictive Lung Disease Following Autologous Stem Cell Transplantation for High Risk Lymphoma

Author

Whalen, Matthew, primary, Hayes, Colin, additional, Braun, Thomas, additional, Myers, Dawson, additional, Magenau, John, additional, Maciejewski, John, additional, Anand, Sarah, additional, Riwes, Mary Mansour, additional, Abusin, Ghada, additional, Lugt, Mark T. Vander, additional, Ghosh, Monalisa, additional, Pawarode, Attaphol, additional, Choi, Sung, additional, Triebwasser, Michael, additional, and Yanik, Gregory A., additional

Published
2024
Full Text
View/download PDF

8. Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation to Mitigate Acute Graft Versus Host Disease: A Phase II Study Clinical Update

Author

Riwes, Mary Mansour, primary, Braun, Thomas, additional, Magenau, John, additional, Geer, Marcus J., additional, Ghosh, Monalisa, additional, Pawarode, Attaphol, additional, Anand, Sarah, additional, Maciejewski, John, additional, King, Darren, additional, Choi, Sung Won, additional, Yanik, Gregory A., additional, Tewari, Muneesh, additional, and Reddy, Pavan, additional

Published
2024
Full Text
View/download PDF

9. MODULAATE (Part 1): An Open-Label, Dose-Finding Phase 2 Evaluation of Alpha-1 Antitrypsin for the Prevention of Graft-Versus-Host Disease in Patients Receiving Hematopoietic Cell Transplantation

Author

Waller, Edmund K., primary, Horwitz, Mitchell, additional, Anand, Sarah, additional, Tey, Siok-Keen, additional, Berger, Mel, additional, Preiss, Ralph, additional, Raychaudhuri, Aparna, additional, Mahajan, Vaibhav, additional, Sarkar, Preenan, additional, Baheti, Gautam, additional, Cooper, Melisa, additional, Lee, Laurie, additional, Zhuplatov, Sergey, additional, Mallee, John, additional, and Deeg, H. Joachim, additional

Published
2024
Full Text
View/download PDF

10. Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.

Author

Frame, David G., Geer, Marcus, Kasha, Salena, Markstrom, Denise, Scappaticci, Gianni, Feeney, Tate, Hayduk, Andrew, Mansoor, Hilary M., Oberfeld, Avery, D'Antonio, Hannah, Anand, Sarah, Sung Won Choi, Maciejewski, John, Pawarode, Attaphol, Riwes, Mary Mansour, Tewari, Muneesh, Magenau, John, and Ghosh, Monalisa

Subjects
NON-Hodgkin's lymphoma, T cells, CD19 antigen, CYTOKINE release syndrome, ELECTRONIC health records
Abstract

Introduction: Lymphodepleting chemotherapy (LDC) is critical to CAR T-cell expansion and efficacy. Despite this, there is not a consensus in the literature regarding the optimal LDC regimen, including dose and frequency. Methods: We retrospectively reviewed consecutive patients at a single institution that received LDC prior to treatment with the CD19 directed CAR T-cell products axicabtagene ciloleucel and tisagenlecleucel. Patients treated at our center received fludarabine 30 mg/m2 and cyclophosphamide 500 mg/m2 for 3 consecutive days prior to May 2019. After this timepoint patients routinely received fludarabine 40 mg/m² and cyclophosphamide 500 mg/m² for 2 consecutive days. Clinical data from each cohort were obtained from the electronic medical record and compared for differences in CAR T-cell efficacy and toxicity. Results: From June 2018 to August 2023, LDC was given to 92 patients prior to CD19 directed CAR T-cell therapy for relapsed non-Hodgkin's lymphoma. Twenty-eight patients received a 3-day regimen, and 64 patients received a 2-day regimen. In the total cohort, 75% of patients received axicabtagene ciloleucel and 25% received tisagenlecleucel. The overall response rates in both the 2-day regimen group and the 3-day regimen group were similar (69% vs 75%, p= 0.21) as were the complete response rates (50% vs 54%, p=0.82). There were no significant differences between the 2-day and 3-day regimens for grade 2-4 cytokine release syndrome (55% vs 50%, p=0.82), grade 2-4 immune effector cell associated-neurotoxicity syndrome (42% vs 29%, p=0.25), or time to resolution of neutropenia or thrombocytopenia. The rate of prolonged platelet recovery lasting greater than 60 days was higher with the 3-day regimen (9% vs 27%, p=0.026). Discussion: As the number of patients eligible for CAR T-cell therapy continues to increase, optimizing each component of therapy is necessary. We show that a 2-day regimen of LDC with fludarabine and cyclophosphamide is feasible without significant impact on CAR T-cell efficacy or toxicity. Prospective studies are necessary to further determine the most effective LDC regimen. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Heightened TLR7 Primes BCR-Activated Cells in Chronic Graft-Versus-Host Disease for Effector Functions

Author

Bracken, Sonali J, primary, Suthers, Amy, additional, DiCioccio, Rachel A., additional, Su, Hsuan, additional, Anand, Sarah, additional, Poe, Jonathan C., additional, Jia, Wei, additional, visentin, jonathan, additional, Basher, Fahmin, additional, Jordan, Collin Z, additional, McManigle, William C, additional, Li, Zhiguo, additional, Hakim, Frances T, additional, Pavletic, Steven Z, additional, Bhuiya, Nazmim, additional, Ho, Vincent T., additional, Horwitz, Mitchell E., additional, Chao, Nelson J., additional, and Sarantopoulos, Stefanie, additional

Published
2023
Full Text
View/download PDF

12. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease

Author

Lin, Chenyu, DiCioccio, Rachel A., Haykal, Tarek, McManigle, William C., Li, Zhiguo, Anand, Sarah M., Poe, Jonathan C., Bracken, Sonali J., Jia, Wei, Alyea, Edwin P., III, Cardones, Adela R., Choi, Taewoong, Gasparetto, Cristina, Grunwald, Michael R., Hennig, Therese, Kang, Yubin, Long, Gwynn D., Lopez, Richard, Martin, Melissa, Minor, Kerry K., Quinones, Victor L. Perez, Sung, Anthony D., Wiggins, Kristi, Chao, Nelson J., Horwitz, Mitchell E., Rizzieri, David A., and Sarantopoulos, Stefanie

Published
2023
Full Text
View/download PDF

13. A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease

Author

Magenau, John M, primary, Jaglowski, Samantha M, additional, Uberti, Joseph, additional, Farag, Sherif S, additional, Mansour Riwes, Mary, additional, Pawarode, Attaphol, additional, Anand, Sarah, additional, Ghosh, Monalisa, additional, Maciejewski, John, additional, Braun, Thomas M, additional, Devenport, Martin, additional, Lu, Susan, additional, Banerjee, Bhramori, additional, DaSilva, Carolyn, additional, Devine, Steven M, additional, Zhang, Mei-Jie, additional, Burns, Linda J, additional, Liu, Yang, additional, Zheng, Pan, additional, and Reddy, Pavan, additional

Published
2023
Full Text
View/download PDF

15. Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients

Author

Coda, John, primary, Raser, Kadee, additional, Anand, Sarah M., additional, Ghosh, Monalisa, additional, Gregg, Kevin, additional, Li, Jinju, additional, Maciejewski, John J., additional, Pawarode, Attaphol, additional, Riwes, Mary M., additional, Tillman, Christina, additional, Polk, Avery, additional, Kandarpa, Malathi, additional, Talpaz, Moshe, additional, Choi, Sung Won, additional, Yanik, Gregory A., additional, Magenau, John M., additional, and Pianko, Matthew J., additional

Published
2022
Full Text
View/download PDF

16. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease

Author

Lin, Chenyu, primary, DiCioccio, Rachel A., additional, Haykal, Tarek, additional, McManigle, William C., additional, Li, Zhiguo, additional, Anand, Sarah M., additional, Poe, Jonathan C., additional, Bracken, Sonali J., additional, Jia, Wei, additional, Alyea, Edwin P., additional, Cardones, Adela R., additional, Choi, Taewoong, additional, Gasparetto, Cristina, additional, Grunwald, Michael R., additional, Hennig, Therese, additional, Kang, Yubin, additional, Long, Gwynn D., additional, Lopez, Richard, additional, Martin, Melissa, additional, Minor, Kerry K., additional, Quinones, Victor L. Perez, additional, Sung, Anthony D., additional, Wiggins, Kristi, additional, Chao, Nelson J., additional, Horwitz, Mitchell E., additional, Rizzieri, David A., additional, and Sarantopoulos, Stefanie, additional

Published
2022
Full Text
View/download PDF

17. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

Author

Abedin, Sameem, primary, Hamadani, Mehdi, additional, Holtan, Shernan G, additional, Schiller, Gary J., additional, Gallogly, Molly, additional, Waller, Edmund K., additional, Kosuri, Satyajit, additional, Abhyankar, Sunil H, additional, Anand, Sarah M., additional, Gooptu, Mahasweta, additional, Cho, Iming, additional, Reed, Simona, additional, Lin, Shih-Yao, additional, Hall, Jesse W, additional, and Martin, Paul J, additional

Published
2022
Full Text
View/download PDF

18. A secondary CD34+ acute lymphoblastic leukemia unmasked and mobilized by G‐CSF in an autologous stem cell donor with testicular cancer.

Author

Cooling, Laura, Kelley, Justin, Sexton, Edison, Anand, Sarah, and Hoffmann, Sandra

Subjects
LYMPHOBLASTIC leukemia, TESTICULAR cancer, ACUTE leukemia, STEM cell donors, CD34 antigen, MULTIPOTENT stem cells
Abstract

Background: Late complications of chemotherapy include treatment‐related secondary leukemias. We describe an unusual case of a new treatment‐related acute lymphoblastic leukemia (t‐ALL) that was unmasked and mobilized by G‐CSF during autologous hematopoietic progenitor cell collection (HPCC) in a young man with testicular cancer. Methods: Electronic chart review of the patient medical history and pertinent laboratory findings. Patient CD34 and blast results were compared to 4249 autologous and 437 allogeneic HPCC performed between 2004 and 2022. In autologous donors, the %blast and %CD34 were compared by linear regression and paired t‐test using commercial software. Results: The patient was a 21‐year‐old male with relapsed testicular cancer referred for G‐CSF cytokine‐only mobilization and autologous HPCC. His pre‐mobilization WBC count and differential were normal. On the day of HPCC, his WBC = 37.9 K/mcL with 12% blasts and 9.75% circulating CD34+ cells. The patient was admitted 9 days after HPCC with a normal WBC count and 15% blasts. He was diagnosed with a pro‐B t‐ALL bearing an t(4:11)(q21:q23) translocation and KMT2A‐AF4 rearrangement. Upon review, this patient had the highest %CD34 among 4686 HPCC and was the only donor with %CD34 > 1% after a cytokine‐only mobilization. Conclusion: We report a case of t‐ALL that mimicked CD34+ HPC and was mobilized by high‐dose G‐CSF. Up to 70% of secondary leukemias bear 11q23/KMT2A rearrangements, which occur at the multipotent stem cell stage and can result in myeloid and lymphoid leukemias. Donors who have received past chemotherapy, especially with topoisomerase II inhibitors, are at increased risk for 11q23/KMT2A leukemias. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. MODULAATE, A 2-Part, Dose-Finding, Efficacy and Safety Trial with Alpha-1 Antitrypsin (AAT) for Prevention of Acute Graft vs. Host Disease (aGVHD): Part 1 Safety and Pharmacokinetic (PK) Results

Author

Mallee, John, primary, Horwitz, Mitchell E., additional, Briggs, Adrienne, additional, Anand, Sarah, additional, Tey, Siok-Keen, additional, Waller, Edmund K., additional, Cooper, Melisa, additional, Baheti, Gautam, additional, Mahajan, Vaibhav, additional, Lee, Laurie, additional, and Deeg, H. Joachim, additional

Published
2022
Full Text
View/download PDF

20. Use of Siltuximab for the Treatment of Severe Immune Effector Cell Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy: Single Center Case Series

Author

Geer, Marcus J., primary, Frame, David, additional, Magenau, John, additional, Maciejewski, John, additional, Anand, Sarah, additional, Riwes, Mary Mansour, additional, Pawarode, Attaphol, additional, Reddy, Pavan, additional, Scappaticci, Gianni B., additional, Markstrom, Denise, additional, and Ghosh, Monalisa, additional

Published
2022
Full Text
View/download PDF

25. Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study

Author

Riwes, Mary Mansour, Golob, Jonathan Louis, Magenau, John M., Lyssiotis, Costas, Shan, Mengrou, Dick, Gregory, Braun, Thomas, Schmidt, Thomas M, Pawarode, Attaphol, Anand, Sarah, Ghosh, Monalisa, Maciejewski, John, King, Darren, Choi, Sung W., Yanik, Gregory, Geer, Marcus Johannes, Hillman, Ethan, Tewari, Muneesh, and Reddy, Pavan

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is limited by acute graft versus host disease (GVHD). GVHD is the principal cause of non-relapse mortality (NRM) and a major cause of morbidity after allo-HCT. Recent published experimental data demonstrated that altering the microbiome-metabolite axis regulates acute GVHD severity. Specifically, short chain fatty acid (SCFA) butyrate was significantly decreased in the intestinal epithelial cells (IECs) of mice experiencing GVHD, while restoring butyrate levels by increasing intestinal butyrate-producing bacteria, reduced experimental acute GI GVHD severity and mortality. Prebiotics usually refer to indigestible carbohydrates that are metabolized by the intestinal microbiota to produce microbial metabolites, such as SCFAs, that serve as nutrients for IECs. Administration of defined quantities of resistant potato starch (RPS), as a prebiotic, to normal healthy human volunteers promoted increase in butyrogenic bacteria and increased intestinal levels of SCFA butyrate to a greater extent than other commercially available resistant starch preparations tested. These data form the rationale for this study and led to prospectively study the clinical feasibility and impact of the administration of RPS as a prebiotic dietary intervention on the intestinal microbiota and its dependent metabolites in allo-HCT recipients.

Published
2023
Full Text
View/download PDF

26. Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score.

Author

Vasbinder A, Catalan T, Anderson E, Chu C, Kotzin M, Murphy D, Cheplowitz H, Diaz KM, Bitterman B, Pizzo I, Huang Y, Xie J, Hoeger CW, Kaakati R, Berlin HP, Shadid H, Perry D, Pan M, Takiar R, Padalia K, Mills J, Meloche C, Bardwell A, Rochlen M, Blakely P, Leja M, Banerjee M, Riwes M, Magenau J, Anand S, Ghosh M, Pawarode A, Yanik G, Nathan S, Maciejewski J, Okwuosa T, and Hayek SS

Subjects
Adult, Humans, Middle Aged, Bone Marrow Transplantation adverse effects, Risk Factors, Retrospective Studies, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, Hematopoietic Stem Cell Transplantation adverse effects, Heart Failure epidemiology, Heart Failure therapy, Heart Failure complications
Abstract

Background: Evidence guiding the pre-hematopoietic stem cell transplantation (HSCT) cardiovascular evaluation is limited. We sought to derive and validate a pre-HSCT score for the cardiovascular risk stratification of HSCT candidates., Methods and Results: We leveraged the CARE-BMT (Cardiovascular Registry in Bone Marrow Transplantation) study, a contemporary multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019 (N=2435; mean age at transplant of 55 years; 4.9% Black). We identified the subset of variables most predictive of post-HSCT cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, heart failure, stroke, atrial fibrillation or flutter, and sustained ventricular tachycardia. We then developed a point-based risk score using the hazard ratios obtained from Cox proportional hazards modeling. The score was externally validated in a separate cohort of 919 HSCT recipients (mean age at transplant 54 years; 20.4% Black). The risk score included age, transplant type, race, coronary artery disease, heart failure, peripheral artery disease, creatinine, triglycerides, and prior anthracycline dose. Risk scores were grouped as low-, intermediate-, and high-risk, with the 5-year cumulative incidence of cardiovascular events being 4.0%, 10.3%, and 22.4%, respectively. The area under the receiver operating curves for predicting cardiovascular events at 100 days, 5 and 10 years post-HSCT were 0.65 (95% CI, 0.59-0.70), 0.73 (95% CI, 0.69-0.76), and 0.76 (95% CI, 0.69-0.81), respectively. The model performed equally well in autologous and allogeneic recipients, as well as in the validation cohort., Conclusions: The CARE-BMT risk score is easy to calculate and could help guide referrals of high-risk HSCT recipients to cardiovascular specialists before transplant and guide long-term monitoring.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results